Company intelligence / Profile preview

WinHealth Investment

Kowloon, Hong Kong

Ownership: Private
Employees: ~547
Development stage: Other

Overview

WinHealth Pharma has established commercial operations across China and Asia for numerous branded and licensed prescription drugs, primarily sourced and licensed from multinational partners. Their Japanese subsidiary received manufacturing/marketing authorization in 2025, expanding reach to Japan for both proprietary and in-licensed products. Public details on specific clinical trial results are limited

Therapeutic areas: Infectious DiseasesRare DiseasesGastroenterologyDermatologyCardiovascularOncology
Modalities: Small moleculeBiologicMonoclonal antibodyRecombinant proteinOther standard pharma modalities
Industry: Biotech

Partnerships

Kyowa KirinOther undisclosed international pharma/biotech licensors and strategic partners for commercialization and CSO services

Beyond the preview

Go deeper on WinHealth Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WinHealth Investment.

Explore the full profile